Luxbright AB (publ) (LXB.ST)
SEK 0.82
(-3.55%)
SEK 0.82
(-3.55%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 854.69 Thousand SEK | 5.3% |
| 2022 | 811.69 Thousand SEK | 11.34% |
| 2021 | 729 Thousand SEK | 18.67% |
| 2020 | 614.29 Thousand SEK | -12.7% |
| 2019 | 703.68 Thousand SEK | -49.75% |
| 2018 | 1.4 Million SEK | 14.43% |
| 2017 | 1.22 Million SEK | 67.97% |
| 2016 | 728.52 Thousand SEK | 757.38% |
| 2015 | 84.97 Thousand SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 2.33 Million SEK | 173.39% |
| 2024 Q2 | 2.33 Million SEK | 0.0% |
| 2023 Q2 | - SEK | 0.0% |
| 2023 Q4 | 855 Thousand SEK | 100.07% |
| 2023 FY | 854.69 Thousand SEK | 5.3% |
| 2023 Q3 | 427.35 Thousand SEK | 0.0% |
| 2023 Q1 | - SEK | -100.0% |
| 2022 Q2 | 355 Thousand SEK | 100.0% |
| 2022 Q4 | 228.34 Thousand SEK | 0.0% |
| 2022 Q3 | 228.34 Thousand SEK | -35.68% |
| 2022 Q1 | 177.5 Thousand SEK | -43.83% |
| 2022 FY | 811.69 Thousand SEK | 11.34% |
| 2021 Q1 | 206.5 Thousand SEK | -57.25% |
| 2021 Q2 | 413 Thousand SEK | 100.0% |
| 2021 Q3 | 158 Thousand SEK | -61.74% |
| 2021 Q4 | 316 Thousand SEK | 100.0% |
| 2021 FY | 729 Thousand SEK | 18.67% |
| 2020 Q4 | 483 Thousand SEK | 100.0% |
| 2020 Q2 | 882.25 Thousand SEK | 100.06% |
| 2020 Q3 | 241.5 Thousand SEK | -72.63% |
| 2020 FY | 614.29 Thousand SEK | -12.7% |
| 2020 Q1 | 441 Thousand SEK | 144.58% |
| 2019 Q3 | 90.5 Thousand SEK | -82.71% |
| 2019 FY | 703.68 Thousand SEK | -49.75% |
| 2019 Q4 | 180.3 Thousand SEK | 99.23% |
| 2019 Q2 | 523.37 Thousand SEK | 100.14% |
| 2019 Q1 | 261.5 Thousand SEK | 0.0% |
| 2018 FY | 1.4 Million SEK | 14.43% |
| 2017 FY | 1.22 Million SEK | 67.97% |
| 2016 FY | 728.52 Thousand SEK | 757.38% |
| 2015 FY | 84.97 Thousand SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Acarix AB (publ) | 6.24 Million SEK | 86.305% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | 99.938% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | 99.938% |
| Arcoma AB | 163.01 Million SEK | 99.476% |
| Bactiguard Holding AB (publ) | 203.99 Million SEK | 99.581% |
| BICO Group AB (publ) | 2.23 Billion SEK | 99.962% |
| Boule Diagnostics AB (publ) | 571.32 Million SEK | 99.85% |
| CellaVision AB (publ) | 677.29 Million SEK | 99.874% |
| Clinical Laserthermia Systems AB (publ) | 8.27 Million SEK | 89.669% |
| Chordate Medical Holding AB (publ) | 976.28 Thousand SEK | 12.454% |
| C-Rad AB (publ) | 424.61 Million SEK | 99.799% |
| Duearity AB (publ) | 1.65 Million SEK | 48.325% |
| Dignitana AB (publ) | 86.06 Million SEK | 99.007% |
| Episurf Medical AB (publ) | 10.3 Million SEK | 91.702% |
| Getinge AB (publ) | 31.82 Billion SEK | 99.997% |
| Scandinavian Real Heart AB (Publ) | - SEK | -Infinity% |
| Iconovo AB (publ) | 7.07 Million SEK | 87.925% |
| Integrum AB (publ) | 104.11 Million SEK | 99.179% |
| Mentice AB (publ) | 273.61 Million SEK | 99.688% |
| OssDsign AB (publ) | 112.15 Million SEK | 99.238% |
| Paxman AB (publ) | 210.11 Million SEK | 99.593% |
| Promimic AB (publ) | 37.07 Million SEK | 97.694% |
| Qlife Holding AB (publ) | 244 Thousand SEK | -250.286% |
| SciBase Holding AB (publ) | 23.24 Million SEK | 96.323% |
| ScandiDos AB (publ) | 60.42 Million SEK | 98.586% |
| Sectra AB (publ) | 2.96 Billion SEK | 99.971% |
| Sedana Medical AB (publ) | 153.86 Million SEK | 99.445% |
| Senzime AB (publ) | 35.75 Million SEK | 97.61% |
| SpectraCure AB (publ) | 318 Thousand SEK | -168.773% |
| Stille AB | 294.89 Million SEK | 99.71% |
| Vitrolife AB (publ) | 3.51 Billion SEK | 99.976% |
| Xvivo Perfusion AB (publ) | 597.54 Million SEK | 99.857% |